TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26621626

Group type: EXPERIMENTAL
Intervention: Cerebral lateral ventricular size (graded on a 0 to 9 scale)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Cortical sulcal width (graded on a 0 to 9 scale)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: White matter hyperintensities (WMH) (graded on a 0 to 9 scale)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Tertiles of ventricular size
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Presence of new ischemic lesions
Number of subjects: 79
Study: 23229237

Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine alcohol base mouthrinse (CLX-A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.1% Chlorhexidine non-alcohol base with 0.1% Formaldehyde (CLX-F)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (negative control)
Number of subjects: 30
Study: 21507715

Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib (1.3 mg/m2, twice per week)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Intravenous bortezomib (1.3 mg/m2, twice per week)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib
Number of subjects: 222

Group type: COMPARATOR
Intervention: Intravenous bortezomib
Number of subjects: 222
Study: 19623185

Group type: COMPARATOR
Intervention: Nutrition intervention component including modifications to the total school food environment, such as federal breakfast, lunch, after school snack and supper programs, a la carte venues, vending machines, and classroom parties.
Number of subjects: 42
Study: 16436397

Group type: EXPERIMENTAL
Intervention: 1‐2‐3 Smokefree programme (video based internet site with tailored strategies)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control group (received nothing for 90 days)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: 1‐2‐3 Smokefree programme (using intent-to-treat model)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control group (using intent-to-treat model)
Number of subjects: 351
Study: 15229342

Group type: EXPERIMENTAL
Intervention: eDiets.com (commercial Internet weight loss program)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Weight loss manual (LEARN Program for Weight Control 2000)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: eDiets.com
Number of subjects: 47

Group type: COMPARATOR
Intervention: Weight loss manual
Number of subjects: 47
Study: 11993078

Group type: EXPERIMENTAL
Intervention: Intercostal nerve blockade (ICB) with ropivacaine 1% (4 times 5 ml)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with 7.5 mg piritramid i.v. before extubation and continuing with 2 mg boli and a 10 min lockout
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intercostal nerve blockade (ICB)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both ICB and PCA
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: ICB
Number of subjects: 43

Group type: COMPARATOR
Intervention: PCA
Number of subjects: 43
Study: 9808415

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 61

Group type: COMPARATOR
Intervention: Colchicine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 8553906

Group type: EXPERIMENTAL
Intervention: High-dose IL-2 (18 million IU/day subcutaneously for 3 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 (6 million IU/day subcutaneously for 5 days) plus MLT (40 mg/day orally)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 30
Study: 2220646

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 607

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 607
Study: 719572

Group type: EXPERIMENTAL
Intervention: Compression garments
Number of subjects: 35
Study: 7058754

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 30 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 60 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 120 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 15 mg (four times daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 30 mg (four times daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (various doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 12
Study: 30669825

Group type: EXPERIMENTAL
Intervention: Schroth therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Classic anti-gravitation exercises
Number of subjects: 50
Study: 29125382

Group type: EXPERIMENTAL
Intervention: Intra-sheath injection of 1ml of 40mg/ml methyl prednisolone acetate
Number of subjects: 166

Group type: COMPARATOR
Intervention: Extra-sheath injection of 1ml of 40mg/ml methyl prednisolone acetate
Number of subjects: 166
Study: 25984794

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) after 8 sessions
Number of subjects: 581
Study: 24452845

Group type: EXPERIMENTAL
Intervention: Interactive video gaming
Number of subjects: 20

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 20
Study: 22480620

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injections into plantar flexor muscles
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline placebo injections
Number of subjects: 15
Study: 20414723

Group type: EXPERIMENTAL
Intervention: Filmed contact
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Simulation of auditory hallucinations
Number of subjects: 143

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 143
Study: 17612811

Group type: EXPERIMENTAL
Intervention: Individualized Piano Instruction (IPI)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 31
Study: 16132480

Group type: EXPERIMENTAL
Intervention: Colonic J-pouch
Number of subjects: 56

Group type: COMPARATOR
Intervention: Side-to-end anastomosis
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 11804663

Group type: EXPERIMENTAL
Intervention: Ethanol (40 g/day) for 4 weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ethanol withdrawal
Number of subjects: 5

Group type: COMPARATOR
Intervention: Non-alcoholic liver disease patients
Number of subjects: 5
Study: 10416728

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 7487127

Group type: EXPERIMENTAL
Intervention: Azasetron (10 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Granisetron (3 mg/day)
Number of subjects: 0
Study: 2148146

Group type: EXPERIMENTAL
Intervention: Low-oestrogen combined pill
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Progestogen-only pill
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 68
Study: 7190495

Group type: EXPERIMENTAL
Intervention: Humid air (80‐90% R.H.) during swimming
Number of subjects: 9

Group type: COMPARATOR
Intervention: Dry air (15‐35% R.H.) during swimming
Number of subjects: 9

Group type: COMPARATOR
Intervention: Treadmill run with room air dried to 25‐30% R.H.
Number of subjects: 9
Study: 29254414

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Pharmacology (PH)
Number of subjects: 59
Study: 28166190

Group type: EXPERIMENTAL
Intervention: Crushed/suspended Stribild + enteral nutrition
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Crushed/suspended Stribild + breakfast
Number of subjects: 24

Group type: COMPARATOR
Intervention: Whole Stribild tablet with breakfast (reference)
Number of subjects: 24
Study: 26530649

Group type: EXPERIMENTAL
Intervention: MoM THA
Number of subjects: 93

Group type: COMPARATOR
Intervention: MoP THA
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MoM THA (women)
Number of subjects: 93

Group type: COMPARATOR
Intervention: MoP THA (women)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MoM THA (men)
Number of subjects: 93

Group type: COMPARATOR
Intervention: MoP THA (men)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MoM THA (elevated cobalt levels)
Number of subjects: 93
Study: 23547240

Group type: EXPERIMENTAL
Intervention: Nebivolol (5-20 mg/d)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Metoprolol (100-300 mg/d)
Number of subjects: 21
Study: 21486442

Group type: EXPERIMENTAL
Intervention: Higher Relative Total Dose Intensity (RTDI)
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: RTDI cut-off levels <85%
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: RTDI above 85%
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Lower RTDI
Number of subjects: 933
Study: 19222455

Group type: EXPERIMENTAL
Intervention: 5-ALA patch-PDT
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo-PDT
Number of subjects: 449

Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 449
Study: 17719935

Group type: EXPERIMENTAL
Intervention: Nebulized 3% hypertonic saline (HS)
Number of subjects: 96

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 96
Study: 15592731

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg/d
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11553421

Group type: EXPERIMENTAL
Intervention: Educational intervention designed to improve self-management ability
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urban residents
Number of subjects: 0
Study: 9395036

Group type: EXPERIMENTAL
Intervention: CALGB trials
Number of subjects: 9
Study: 7967349

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (0.5 ng/kg/min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (1.0 ng/kg/min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (2.5 ng/kg/min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Calcium channel blocker (nifedipine) pretreatment
Number of subjects: 7
Study: 3302010

Group type: EXPERIMENTAL
Intervention: Sucralfate, 1g twice daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 84
Study: 30782617

Group type: EXPERIMENTAL
Intervention: Lower-fat diet (20% energy from fat)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Higher-fat diet (40% energy from fat)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Moderate-fat diet (30% energy from fat)
Number of subjects: 217
Study: 28236919

Group type: COMPARATOR
Intervention: Tunneled central venous catheters (TCVC)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Early cannulation arteriovenous grafts (ecAVG) with or without arteriovenous fistula (AVF)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Cost comparison between TCVC and ecAVG
Number of subjects: 121
Study: 26129694

Group type: EXPERIMENTAL
Intervention: Preventive Cognitive Therapy (PCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 0
Study: 23527868

Group type: EXPERIMENTAL
Intervention: Moderately intoxicating dose of alcohol (mean blood alcohol concentration = 0.076 g/dl)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 40
Study: 19819688

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (Group A)
Number of subjects: 108

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (Group B)
Number of subjects: 108
Study: 18977646

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate/formoterol combination via single inhaler
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate/formoterol combination via separate inhalers
Number of subjects: 645

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (500 microg bid) via CFC pMDI
Number of subjects: 645

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (500 microg bid) via CFC pMDI and formoterol (12 microg bid) via DPI
Number of subjects: 645
Study: 16979990

Group type: EXPERIMENTAL
Intervention: CsA‐everolimus‐based regimen
Number of subjects: 12

Group type: COMPARATOR
Intervention: CsA‐azathioprine‐based regimen
Number of subjects: 12
Study: 13678928

Group type: EXPERIMENTAL
Intervention: Insulin (10 IU)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study: 11003253

Group type: EXPERIMENTAL
Intervention: Human ultralente insulin injected at 17.00 h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Human ultralente insulin injected at 22.00 h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular insulin injected before dinner
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Human ultralente insulin (in general)
Number of subjects: 10
Study: 8671110

Group type: EXPERIMENTAL
Intervention: Different recruitment strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial participation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial completion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early trial dropout
Number of subjects: 0
Study: 1345332

Group type: EXPERIMENTAL
Intervention: Cholesterol reduction (approximately 5%)
Number of subjects: 0
Study: 6418897

Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy (thiotepa or VM26)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Transurethral resection alone
Number of subjects: 123
Study: 30888448

Group type: EXPERIMENTAL
Intervention: All-inside technique with ST4 autograft
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional technique with ST/G autograft
Number of subjects: 90
Study: 29742264

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12% mouthwash (CHX)
Number of subjects: 822

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study: 25822598

Group type: EXPERIMENTAL
Intervention: Surgical treatment (techniques chosen by surgeons)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Non-surgical treatment (initial sling immobilization followed by active rehabilitation)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 250

Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 250
Study: 24023786

Group type: EXPERIMENTAL
Intervention: simvastatin 40 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: ezetimibe 10 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: simvastatin 40 mg and ezetimibe 10 mg combination
Number of subjects: 72
Study: 21774281

Group type: EXPERIMENTAL
Intervention: Special education group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine education group
Number of subjects: 200
Study: 19002384

Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg plus mFOLFOX6
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg plus mFOLFOX6
Number of subjects: 17
Study: 17255230

Group type: EXPERIMENTAL
Intervention: Allopurinol (900 mg/d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 15599989

Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Excipient
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderately active topical corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical corticosteroids
Number of subjects: 0
Study: 11740820

Group type: COMPARATOR
Intervention: Neovastat in addition to induction chemotherapy/radiotherapy
Number of subjects: 482

Group type: COMPARATOR
Intervention: Neovastat as a monotherapy
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Neovastat
Number of subjects: 482
Study: 7620239

Group type: EXPERIMENTAL
Intervention: Adrenaline (5 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Salbutamol (5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2836651

Group type: EXPERIMENTAL
Intervention: hCRF (2 micrograms/kg body weight) with naloxone (1.6 mg i.v. bolus, followed by an infusion at a rate of 1.2 mg/h)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: hCRF alone
Number of subjects: 6

Group type: COMPARATOR
Intervention: hCRF with naloxone
Number of subjects: 6
Study: 29847831

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral analysis system of psychotherapy (CBASP)
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Antidepressant pharmacotherapy
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Combination therapy (CBASP + pharmacotherapy)
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Monotherapy (either CBASP or pharmacotherapy)
Number of subjects: 1036
Study: 28802440

Group type: EXPERIMENTAL
Intervention: Debiasing technique 'considering the alternative'
Number of subjects: 0
Study: 26167944

Group type: EXPERIMENTAL
Intervention: Bibliotherapy with therapist support
Number of subjects: 89

Group type: COMPARATOR
Intervention: Bibliotherapy without therapist support
Number of subjects: 89
Study: 23540233

Group type: EXPERIMENTAL
Intervention: Anti-tobacco educational programme
Number of subjects: 859

Group type: COMPARATOR
Intervention: Control group (no educational actions)
Number of subjects: 859
Study: 21508655

Group type: EXPERIMENTAL
Intervention: Power-microdebrider-assisted inferior turbinoplasty (PAT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Submucosal resection (SMR)
Number of subjects: 46
Study: 18294229

Group type: EXPERIMENTAL
Intervention: Ultrasonic mechanical instrumentation (UMI) with chlorhexidine (CHX) 0.02%
Number of subjects: 19

Group type: COMPARATOR
Intervention: Ultrasonic mechanical instrumentation (UMI) alone
Number of subjects: 19
Study: 16549259

Group type: EXPERIMENTAL
Intervention: Headache Impact Test (HIT) administered at baseline and 6-week follow-up
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Patients reporting 'somewhat better' change
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Patients reporting no change
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Minimum important difference (MID) estimation
Number of subjects: 71
Study: 14596323

Group type: EXPERIMENTAL
Intervention: Mg citrate
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Mg amino-acid chelate
Number of subjects: 46

Group type: COMPARATOR
Intervention: Mg oxide
Number of subjects: 46
Study: 11029398

Group type: COMPARATOR
Intervention: VEGF-A(165), VEGF-A(189), VEGF-B, VEGF-R(1) mRNA and protein levels in DCM patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VEGF-C mRNA and protein levels in ICM patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capillary density in DCM patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capillary density in ICM patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Collagen levels in DCM patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Muscular hypertrophy in DCM and ICM patients
Number of subjects: 0
Study: 9715552

Group type: EXPERIMENTAL
Intervention: Once daily gentamicin regimen (4 mg/kg Q 24 h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional gentamicin regimen (2.5 mg/kg Q 12 h)
Number of subjects: 18
Study: 8285548

Group type: EXPERIMENTAL
Intervention: 20 ml of 0.25% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 20 ml of saline
Number of subjects: 60
Study: 3543234

Group type: EXPERIMENTAL
Intervention: MTC plus P
Number of subjects: 200

Group type: COMPARATOR
Intervention: MTC alone
Number of subjects: 200
Study: 29361197

Group type: EXPERIMENTAL
Intervention: Add-on structured goal-planning and supportive telephone follow-up rehabilitation program
Number of subjects: 389

Group type: COMPARATOR
Intervention: Traditional rehabilitation
Number of subjects: 389
Study: 27367263

Group type: EXPERIMENTAL
Intervention: Treatment 'failures' (heavy drinkers) in COMBINE
Number of subjects: 2490

Group type: EXPERIMENTAL
Intervention: Treatment 'failures' (heavy drinkers) in Project MATCH
Number of subjects: 2490

Group type: COMPARATOR
Intervention: Treatment 'successes' (non-heavy drinkers)
Number of subjects: 2490
Study: 26042037

Group type: COMPARATOR
Intervention: 250 mg cocoa supplementation (acute)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 250 mg cocoa supplementation (sub-chronic)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 40
Study: 23816723

Group type: EXPERIMENTAL
Intervention: Fosinopril (5-40 mg/day)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Dioscorea bulbifera (500 mg BD)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control (neither drug)
Number of subjects: 137
Study: 20085544

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg/kg
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg/kg
Number of subjects: 465

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 465
Study: 18720882

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone combined with conventional methods
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone injection combined with conventional methods
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection via external ear combined with conventional methods
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection via pharyngotympanic tube combined with conventional methods
Number of subjects: 84
Study: 16051416

Group type: EXPERIMENTAL
Intervention: Propranolol (2 mg or 4 mg i.v.) combined with oxytocin
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo combined with oxytocin
Number of subjects: 107
Study: 12787540

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin and aspirin
Number of subjects: 0
Study: 11093393

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg three times daily for five days
Number of subjects: 174

Group type: COMPARATOR
Intervention: Paracetamol 500 mg with codeine 30 mg six hourly for 5 days
Number of subjects: 174
Study: 8994559

Group type: EXPERIMENTAL
Intervention: Comprehensive psychosocial research protocol
Number of subjects: 169

Group type: COMPARATOR
Intervention: Non-recovered group (NR)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Recovered group (R)
Number of subjects: 169
Study: 8402763

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (healthy, normotensive)
Number of subjects: 28
Study: 3957487

Group type: EXPERIMENTAL
Intervention: Deriphyllin-Digoxin tablets
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lanoxin
Number of subjects: 14